Case Report: Rare Peripheral Neuropathy With Abdominal Wall Allodynia in Extensive‐Stage Small‐Cell Lung Cancer Treated Using Durvalumab
Thoracic Cancer · 2026-07 · 17 (14)
DOI: 10.1111/1759-7714.70368 ↗Kurz gefasst
Fallbericht in der Zeitschrift Thoracic Cancer, online erschienen am 26.07.2026. Verfasst von Ruidan Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory and Critical Care Medicine Department, Norinco General Hospital, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Abdominal Wall, Antibodies, Monoclonal, Antineoplastic Agents, Immunological, Hyperalgesia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, The Sichuan Provincial Natural Science Fund, The Science and Technology Bureau of Chengdu.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs), such as PD‐1/PD‐L1 inhibitors, have revolutionized the treatment of extensive‐stage small‐cell lung cancer (ES‐SCLC). Chemotherapy combined with PD‐1 or PD‐L1 inhibitors has become the standard first‐line treatment for ES‐SCLC. However, with the broad application of immunotherapy, adverse events associated with this therapy have been increasingly reported by clinicians. The identification of atypical and specific manifestations of immune‐related adverse events (irAEs) requires accumulated experience on the part of clinicians. In this article, we report the case of a patient over 50 years of age who was initially diagnosed with ES‐SCLC. Clinical symptoms mainly manifested as allodynia of the abdominal wall following PD‐L1 inhibition immunotherapy. This symptom progressed with continued immunotherapy and resolved after cessation of immunization and treatment with prednisone. A peripheral neuropathy antibody test revealed anti‐GM4 IgG antibody positivity. On the basis of the patient's clinical manifestations and medication history described above, a diagnosis of immune‐related peripheral neuropathy was made. In this case, the irAE severely hindered the treatment process and impaired the patient's quality of life. Through this case report and a review of the literature, we aim to explore how to timely and accurately identify irAEs in immunotherapy, especially nonspecific irAEs, and provide timely treatment to improve patient quality of life and survival and immunotherapy precision and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Respiratory and Critical Care Medicine Department, Norinco General Hospital, Xi'an, Shaanxi, China.
- West China School of Medicine, Sichuan University, Chengdu, Sichuan, China.
- Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
ORCID-Profile: Zhen Li, Xiaoqian Zhai, Jie Shao, Jiewei Liu
Förderung
- National Natural Science Foundation of China
- The Sichuan Provincial Natural Science Fund
- The Science and Technology Bureau of Chengdu
- Guangdong Association of Clinical Trials (GACT)/Chinese Thoracic Oncology Group (CTONG) and Guangdong Provincial Key Lab of Translational Medicine in Lung Canc…
Zitieren
APA
Li, R., Li, Z., Zhai, X., Shao, J., Wang, Y., Zhou, Q., & Liu, J. (2026). Case Report: Rare Peripheral Neuropathy With Abdominal Wall Allodynia in Extensive‐Stage Small‐Cell Lung Cancer Treated Using Durvalumab. Thoracic Cancer, 17(14). https://doi.org/10.1111/1759-7714.70368
Vancouver
Li R, Li Z, Zhai X, Shao J, Wang Y, Zhou Q, et al. Case Report: Rare Peripheral Neuropathy With Abdominal Wall Allodynia in Extensive‐Stage Small‐Cell Lung Cancer Treated Using Durvalumab. Thoracic Cancer. 2026;17(14). doi:10.1111/1759-7714.70368
BibTeX
@article{Li2026,
author = {Li, Ruidan and Li, Zhen and Zhai, Xiaoqian and Shao, Jie and Wang, Yaqin and Zhou, Qinghua and Liu, Jiewei},
title = {Case Report: Rare Peripheral Neuropathy With Abdominal Wall Allodynia in Extensive‐Stage Small‐Cell Lung Cancer Treated Using Durvalumab},
journal = {Thoracic Cancer},
year = {2026},
volume = {17},
number = {14},
doi = {10.1111/1759-7714.70368}
}
EUVIMED